Evidence map›Paper›PMID 24166494›Full record

ArticleOncogene2014

A gene signature of bone metastatic colonization sensitizes for tumor-induced osteolysis and predicts survival in lung cancer.

D Luis-Ravelo, I Antón, C Zandueta, K Valencia, C Ormazábal, S Martínez-Canarias, E Guruceaga, N Perurena, S Vicent, J De Las Rivas and 1 more

Abstract read
PubMed Publisher
In one paragraph

Article in Oncogene, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.

0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed
2.8field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

30 citing papers in PubMed, 42 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. PITX1 plays essential functions in cancer.Frontiers in oncology · 2023
    Review
  6. Article
  7. Article
  8. Review
  9. Review
  10. Review
  11. Article
  12. Article
  13. Article
  14. Review
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

D Luis-RaveloDivision of Oncology, Adhesion and Metastasis Laboratory, University of Navarra, Pamplona, Spain.
I AntónDivision of Oncology, Adhesion and Metastasis Laboratory, University of Navarra, Pamplona, Spain.
C ZanduetaDivision of Oncology, Adhesion and Metastasis Laboratory, University of Navarra, Pamplona, Spain.
K ValenciaDivision of Oncology, Adhesion and Metastasis Laboratory, University of Navarra, Pamplona, Spain.
C OrmazábalDivision of Oncology, Adhesion and Metastasis Laboratory, University of Navarra, Pamplona, Spain.
S Martínez-CanariasDivision of Oncology, Adhesion and Metastasis Laboratory, University of Navarra, Pamplona, Spain.
E GuruceagaBioinformatics and Proteomics Unit, Center for Applied Medical Research (CIMA), University of Navarra, Pamplona, Spain.
N PerurenaDivision of Oncology, Adhesion and Metastasis Laboratory, University of Navarra, Pamplona, Spain.
S Vicent1] Division of Oncology, Adhesion and Metastasis Laboratory, University of Navarra, Pamplona, Spain [2] Department of Histology and Pathology, School of Medicine, University of Navarra, Pamplona, Spain.
J De Las RivasBioinformatics and Functional Genomics Research Group, Cancer Research Center, University of Salamanca (CSIC/USAL), Salamanca, Spain.
F LecandaDivision of Oncology, Adhesion and Metastasis Laboratory, University of Navarra, Pamplona, Spain.
Universidad de Navarra · ESCentro de Investigación del Cáncer · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Bone metastasis of lung adenocarcinoma (AC) is a frequent complication of advanced disease. The purpose of this study was to identify key mediators conferring robust prometastatic activity with clinical significance. We isolated highly metastatic subpopulations (HMS) using a previously described in vivo model of lung AC bone metastasis. We performed transcriptomic profiling of HMS and stringent bioinformatics filtering. Functional validation was assessed by overexpression and lentiviral silencing of single, double and triple combination in vivo and in vitro. We identified HDAC4, PITX1 and ROBO1 that decreased bone metastatic ability after their simultaneous abrogation. These effects were solely linked to defects in osseous colonization. The molecular mechanisms related to bone colonization were mediated by non-cell autonomous effects that include the following: (1) a marked decrease in osteoclastogenic activity in vitro and in vivo, an effect associated with reduced pro-osteoclastogenic cytokines IL-11 and PTHrP expression levels, as well as decreased in vitro expression of stromal rankl in conditions mimicking tumor-stromal interactions; (2) an abrogated response to TGF-β signaling by decreased phosphorylation and levels of Smad2/3 in tumor cells and (3) an impaired metalloproteolytic activity in vitro. Interestingly, coexpression of HDAC4 and PITX1 conferred high prometastatic activity in vivo. Further, levels of both genes correlated with patients at higher risk of metastasis in a clinical lung AC data set and with a poorer clinical outcome. These findings provide functional and clinical evidence that this metastatic subset is an important determinant of osseous colonization. These data suggest novel therapeutic targets to effectively block lung AC bone metastasis.

Indexed as

Gene Expression ProfilingAdenocarcinomaAdenocarcinoma of LungAnimalsBone NeoplasmsCell Line, TumorGene Expression Regulation, NeoplasticHistone DeacetylasesHumansLung NeoplasmsMiceMice, NudeNeoplasms, ExperimentalNerve Tissue ProteinsOsteoclastsOsteolysisHistone DeacetylasesNerve Tissue ProteinsPaired Box Transcription Factors

Identifiers

PMID24166494
OpenAlexW2036795437

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.